inhalation technique is not fully addressed, despite the FDA recommendation that the technique should be trained using an InSpire, a spacer device. This problem of a consistent inhaler technique when patients use MDIs has been extensively reported and hence could affect the reproducibility of any method related to lung deposition in asthmatics, despite extensive training of the technique. Furthermore, this variability of salbutamol deposition would be enhanced by the pathophysiology of a patient’s respiratory tract. Variability of the biosassay will also be introduced by the training effect of the inhaler technique with respect to inhaler therapy, hyperresponsiveness due to previous bronchoprovocation, and the length of salbutamol washout periods. Furthermore, the protocol is very demanding on the asthmatic subjects and our projection is that the drop out rate would be high which, together with the strict inclusion criteria, may introduce bias. Nevertheless, to answer the criticism in the two letters, we are planning clinical studies to compare our urine excretion method with a bronchoprovocation test and the influence of inhaler technique will be studied first.

In vivo deposition studies using a radio label have indicated that the bronchodilator response seems to depend on the total amount delivered to the lung. A recently reported abstract, using labelled salbutamol aerosols, has shown differences in regional lung deposition related to the technique and, when total lung deposition was high, there was a corresponding increase in the amount delivered to the different regions of the lung. This is why we will evaluate the influence of inhaler technique in our bronchoprovocation studies. An ongoing study in our laboratories is showing a linear relationship between one, two, three, four, and five presses (12 subhuffs). All inhaled products contain patient information leaflets describing the inhaler technique which should be used, and examination of these reveals different instructions. It may be the confusion caused by these differences which causes patients to complain. If the pharmaceutical industry cannot agree on the standardisation of the information on how to use an MDI, then perhaps the British Thoracic Society should provide these guidelines. Any argument that different techniques are recommended because of the MDI formulations, characteristics, etc is not substantiated in the literature.


16 Zainudin BMZ, Biddcombe MS, Tolife EJ, Sprig SG. Comparison on bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, an automated puff and as a nebulised solution. Thorax 1990; 45:469–73.

Contradictory data exist regarding the identification of cortisol in lungs of HPS patients with pulmonary fibrosis. Pigment-laden macrophages were seen in some patients but not in others. In one case no cortisol was detected, and in another case the cortisol concentration was identified. In the first of two brothers with HPS and intestinal fibrosis we observed numerous pigment-laden macrophages in the lungs at necropsy, but none in the second, despite having more severe pulmonary fibrosis. The deposition of cortisol cannot therefore be the only cause of pulmonary fibrosis in patients with HPS.

WERNER WÖCKEL
Department of Pathology
Zentralzentralklinikum Gauing
D 82131 Gauing/Munich, Germany

JOACHIM SÖLTZ
Von-Rokitansky-Strasse 15,
D 86356 Neu-Ulm, Germany


Combined chemotherapy and radiotherapy in advanced pulmonary blastoma

We were interested to read the recent case report of Dr Chin et al (August 1994;49: 836–9) describing a case of pulmonary blastoma in an adult presenting as a chronic loculated effusion. We admitted a 57 year old man in 1991 with left shoulder pain, hoarseness, dyspnoea and Homer’s syndrome. Chest radiography revealed a 11 x 12 cm mass in the upper zone of the left hemithorax. Transthoracic fine needle aspiration and bronchoscopy the left vocal cord was paralysed and the left upper lobe bronchus obliterated with a necrotic lesion. Because of the localisation of the lesion, transthoracic lung biopsy was performed and histology examination revealed a pulmonary blastoma. A computed tomographic scan revealed mediastinal invasion by the mass. No distant metastases were detected. The patient was inoperable and palliative treatment was reported according to the use of chemotherapy, radiotherapy alone, or in combination. We gave combined modality treatment using cisplatin, etoposide, and adriamycin as chemotherapy. After two cycles of chemotherapy 6000 cGy radiotherapy was given to the lesion and a 75% regression was noted in the tumour size.
mass. After radiotherapy two further cycles of chemotherapy were given. Unfortunately the patient died of neutropenic sepsis in the 10th month of treatment.

We believe that combined chemotherapy and radiotherapy can be used in this immunohistopathologically and clinically rare tumour.

SERAP HASTÜRK
YURDANUR ERDOĞAN
AYSE ÖZYILDIRIM
BCE AKIR
YILDIZ TEKE

Austärk Chest Diseases Hospital, Ankara, Turkey


BOOK NOTICE


Epidemiology of Lung Cancer is a comprehensive overview of this malignancy in terms of environmental causes, lifestyle factors, familial aggregations, individual susceptibility, and genetic determinants. These and other circumstances of exposure are covered in separate chapters, with each chapter standing on its own. The careful reader will achieve, in a time effective way, a nicely balanced, comprehensive update of what is known today about factors capable of increasing or decreasing the incidence of lung cancer in human populations.

The critical reviews and the summing up of evidence on each of the human exposures are based on empirical findings, mainly epidemiological studies in the form of population-based investigations or hospital-based multicentre studies of lung cancer conducted around the world during the last five decades. In most cases the results are studied in the light of evidence of carcinogenicity in experimental animals and other available information on genetic and related effects of the exposure. Exposures considered exhaustively are tobacco smoking (active and passive) - which is by far the most important single risk factor for lung cancer, air pollution, radon, asbestos and manmade fibres, arsenic, silica, diet and - most importantly - interactions thereof, in particular with tobacco smoking. In addition, a full chapter is devoted to the documentation and discussion of the role of individual susceptibility for developing lung cancer.

Overall, the book is well written, clearly organised, and comprehensive in scope. The authors who have contributed to this work are well recognised in the field. In my opinion, it is a very useful book for anyone who is involved in the treatment and care of patients with lung cancer. As written by Sir Richard Doll in the introduction chapter: "Epidemiology has already taught us enough for it to be possible to confirm that lung cancer ceases to be the most common form of fatal cancer throughout the world and that it returns to the place it occupied in the nineteenth century among the least common human cancers, if society is prepared to act on the knowledge obtained." -JHO

CORRECTION

New perspectives on inhaled drug delivery and systemic bioactivity

In the editorial entitled "New perspectives on inhaled drug delivery and systemic bioactivity" by B J Lipworth, which appeared on pages 105-110 of the February issue, figure 2 on page 106 was incorrectly labelled; 13 µg in part A should have read 13% and 35 µg in part B should have read 33%. The figure is reproduced here with the labelling correctly applied.

105-110

Figure 2. Schematic representation of systemic bioavailability of (A) fluticasone propionate and (B) budesonide given by respective dry powder inhaler devices.
Combined chemotherapy and radiotherapy in advanced pulmonary blastoma.
S Hastürk, Y Erdogan, A Ozyildirim, E Cakir and Y Teke

Thorax 1995 50: 591-592
doi: 10.1136/thx.50.5.591-a

Updated information and services can be found at:
http://thorax.bmj.com/content/50/5/591.2.citation

Email alerting service
These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/